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1.	Introduction	
	
Various	 pyridazine‐annulated	 heterocycles	 have	 been	
attracted	 considerable	 interest	 because	 their	 derivatives	
exhibit	a	wide	range	of	pharmacological	activities	[1‐4].	A	subs‐
tantial	 number	 of	 pyridazines	 have	 been	 reported	 to	 possess	
and	 are	 often	 employed	 as	potent	 analgesic	 [5],	 antimicrobial	
[6,7],	 anti‐inflammatory	 [8],	 antioxidant	 [9],	 antiplatelet	 [10],	
anticancer	 [11],	 anticonvulsant	 [12],	 antifeedant	 [13],	 anti‐
hypertensive	[14],	and	antidiabetic	[15].	Moreover,	pyridazines	
are	 useful	 intermediates	 in	 the	 construction	 of	 several	 other	
heterocycles	[16,17].	With	all	the	above	facts	in	mind	and	as	a	
part	 of	 our	 program	 directed	 towards	 the	 synthesis	 of	 poly‐
functionalized	 substituted	 5‐heterocyclo‐8‐hydroxyquinolines	
of	potential	biologically	interest	[18‐22],	we	have	devoted	some	
efforts	 to	 the	 construction	 of	 a	 novel	 ethyl	 6‐(8‐hydroxy	
quinolin‐5‐yl)‐3‐methylpyridazin‐4‐carboxylate	 (4)	 as	 a	 con‐
veniently	 accessible	 precursor	 for	 the	 synthesis	 of	 some	
hitherto	unreported	substituted	8‐quinolinolinyl‐5‐pyridazines	
and	 their	 related	 derivatives	 in	 one‐pot	 three	 component	
environ‐mental	friendly	method	[23].	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
Melting	points	were	determined	on	a	Kofler	melting	point	
apparatus.	IR	spectra	were	recorded	on	a	Pye	Unicam	SP3‐100	
spectrophotometer	using	the	KBr	wafer	technique.	The	1H	NMR	
spectra	were	recorded	on	a	Bruker	ARX	200	spectrometer	(200	
MHz	 for	 1H	 and	 50	 MHz	 for	 13C)	 at	 the	 Faculty	 of	 Science,	
University	 of	 King	 Saud,	 Saudi	Arabia,	 Riyadh	 and	 on	 a	 Jeol	 a	
400	MHz	 (400	MHz	 for	 1H	and	100	MHz	 for	 the	 13C)	at	Assiut	
University	using	CDCl3	and	DMSO‐d6	as	solvents.	Mass	spectra	
were	 taken	 on	 a	 JEOL	 JMS600	 spectrometer	 at	 an	 ionizing	
potential	of	70	eV	(EI)	at	Assiut	University.	Elemental	analyses	
were	recorded	on	Gmbh	VarioEL	V2.3	Micro	analyzer	at	Assiut	
University	 and	 they	 were	 found	 to	 be	 within	 ±0.4%	 of	 the	
theoretical	values.	
	
2.2.	Synthesis	
	
2.2.1.	Synthesis	of	(8‐hydroxyquinolin‐5‐yl)(oxo)	
acetaldehyde	(2)	
	
The	 starting	 compound	 5‐acetyl‐8‐hydroxyquinoline	 (1)	
was	prepared	following	reported	procedures	[24].		
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Scheme	1
	
	
5‐Acetyl‐8‐hydroxyquinoline	 (1)	 (2.21	 g,	 10	 mmol)	 and	 SeO2	
(5.55	g,	50	mmol)	were	dissolved	 in	a	mixture	of	dioxane	(80	
mL)	and	water	 (5	mL)	and	 refluxed	 for	8	h.	After	 filtration	of	
the	 black	 selenium	 powder,	 the	 clear	 filtrate	 as	 concentrated	
nearly	 to	 dryness.	 Toluene	 (40	 mL)	 was	 added,	 the	 reaction	
mixture	 was	 refluxed	 for	 2	 h,	 decanted	 from	 the	 remaining	
residue	 and	 the	 solvents	 were	 evaporated	 to	 leave	 yellow	
needles	 after	 cooling.	 The	 crystals	 were	 filtered	 off,	 washed	
with	 small	 amount	 of	 ethanol,	 dried	 and	 crystallized	 from	
ethanol	 to	 give	 compound	2	 (Scheme	1).	 Color:	 Yellow.	 Yield:	
62%.	M.p.:	139‐141	°C.	FT‐IR	(KBr,	ν,	cm−1):	1676,	(C=O),	1665	
(HC=O).	 1H	 NMR	 (200	MHz,	 DMSO‐d6,	 δ,	 ppm):	 7.03‐8.81	 (m,	
6H,	5	Ar‐H,	OH),	10.12	(s,	1H,	CHO).	13C	NMR	(100	MHz,	DMSO‐
d6,	 δ,	 ppm):	 201.1,	 189.6,	 155.7,	 154.3,	 150.3,	 148.7,	 144.4,	
129.9,	128.8,	125.4,	115.3.	MS	(EI,	m/z	 (%)):	201.23	(M+.,	75).	
Anal.	 calcd.	 for	C11H7NO3:	 C,	 65.67;	H,	 3.51;	N,	6.96.	 Found:	 C,	
65.96;	H,	3.76;	N,	7.24%.		
	
2.2.2.	Synthesis	of	ethyl	6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methyl	
pyridazin‐4‐carboxylate	(4)	
	
To	 a	mixture	 of	 compound	2	 (4.02	 g,	 20	mmol)	 and	 ethyl	
acetoacetate	(2.6	g,	20	mmol)	in	water	(60	mL),	was	gradually	
added	hydrazine	hydrate	(10	mmol)	at	room	temperature;	the	
resultant	 mixture	 was	 stirred	 for	 1	 h.	 During	 which	 time,	 a	
precipitate	was	formed,	and	then	it	was	filtered	off	and	washed	
with	water.	The	crude	product	was	purified	by	recrystallization	
from	 ethanol	 to	 give	 compound	4	 (Scheme	 1).	 Color:	 Yellow.	
Yield:	82%.	M.p.:	177‐179	°C.	FT‐IR	(KBr,	ν,	cm−1):	2980,	2885	
(CH‐	 aliphatic),	 1732	 (C=O),	 1620	 (C=N).	 1H	 NMR	 (200	MHz,	
DMSO‐d6,	δ,	ppm):	1.35	(t,	J	=	7.4	Hz,	3H,	CH3),	3.15	(s,	3H,	CH3),	
4.25	 (q,	 J	 =	 7.4	 Hz,	 2H,	 CH2),	 7.25‐8.80	 (m,	 7H,	 5	 Ar‐H,	 CH‐
pyridazine,	OH).	 13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	169.2,	
155.3,	 152.2,	 150.4,	 148.4,	 140.8,	 139.6,	 129.3,	 127.2,	 125.5,	
124.3,	 122.9,	 115.8,	 112.3,	 62.7,	 22.4,	 14.6.	MS	 (EI,	m/z	 (%)):	
309.09	(M+.,	74).	Anal.	calcd.	for	C17H15N3O3:	C,	66.01;	H,	4.89;	N,	
13.58.	Found:	C,	66.47;	H,	5.16;	N,	13.95%.	
	
2.2.3.	Synthesis	of	6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methyl	
pyridazine‐4‐carbohydrazide	(8)	
	
To	 a	 suspension	 of	 compound	 4	 (3.09	 g,	 10	 mmol)	 in	
ethanol	(30	mL),	hydrazine	hydrate	(20	mmol)	was	added	and	
the	mixture	was	 heated	 under	 reflux	 for	 4	 h.	 The	 precipitate	
was	 collected	 by	 filtration	 and	 recrystallized	 from	 ethanol	 to	
give	 compound	8	 (Scheme	2).	Color:	Yellow.	Yield:	80%.	M.p.:	
303‐305	°C.	FT‐IR	(KBr,	ν,	cm−1):	3400,	3350,	3200	(NH2,	NH),	
2995	 (CH‐aliphatic),	 1665	 (C=O),	 1620	 (C=N).	 1H	 NMR	 (200	
MHz,	CDCl3,	δ,	ppm):	2.95	(s,	3H,	CH3),	4.42	(s,	2H,	NH2),	7.30‐
8.89	(m,	7H,	5	Ar‐H,	CH‐pyridazine,	OH),	10.14	(s,	1H,	NH).	13C	
NMR	 (100	MHz,	DMSO‐d6	 δ,	 ppm):	 166.6,	 159.2,	 156.1,	146.4,	
146.1,	 140.2,	 138.3,	 129.0,	 128.9,	 125.1,	 123.6,	 120.5,	 118.2,	
111.9,	18.2.	MS	(EI,	m/z	(%)):	295.18	(M+.,	62).	Anal.	calcd.	for	
C15H13N5O2:	C,	61.01;	H,	4.44;	N,	23.72.	Found:	C,	61.44;	H,	4.81;	
N,	23.98%.	
	
2.2.4.	Synthesis	of	5‐[6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methyl	
pyridazin‐4‐yl]‐1,3,4‐oxadiazole‐2(3H)‐thione	(9)		
	
A	 mixture	 of	 acid	 hydrazide	 (8)	 (2.95	 g,	 10	 mmol),	
potassium	hydroxide	(0.56	g,	10	mmol),	carbon	disulfide	(1.29	
g,	17	mmol),	and	ethanol	(70	mL)	was	heated	under	reflux	with	
stirring	 until	 the	 evolution	 of	 hydrogen	 sulfide	 ceased	 (9	 h).	
Ethanol	 was	 distilled	 off	 under	 reduced	 pressure	 and	 the	
residue	was	 dissolved	 in	water	 and	 then	 acidified	with	 dilute	
hydrochloric	acid	(10%).	The	resulting	precipitate	was	filtered,	
washed	with	water,	 dried,	 and	 recrystallized	 from	 ethanol	 to	
give	 compound	9	 (Scheme	2).	Color:	Yellow.	Yield:	69%.	M.p.:	
216‐218	 °C.	 FT‐IR	 (KBr,	 ν,	 cm−1):	 3250	 (NH),	 2990	 (CH‐
aliphatic),	1365	(C=S),	1620	(C=N).	1H	NMR	(400	MHz,	DMSO‐
d6,	 δ,	 ppm):	 3.05	 (s,	 3H,	 CH3),	 7.25‐8.85	 (m,	 7H,	 5	 Ar‐H,	 CH‐
pyridazine,	OH),	10.14	(s,	1H,	NH).	 13C	NMR	(100	MHz,	DMSO‐
d6,	 δ,	 ppm):	 162.7,	 155.3,	 152.1,	 147.7,	 138.3,	 130.1,	 126.3,	
125.4,	123.8,	120.4,	120.1,	116.3,	115.3,	112.5,	113.4,	18.4.	MS	
(EI,	m/z	 (%):	337.28	(M+.,	47).	Anal.	calcd.	for	C16	H11N5O2S:	C,	
56.96;	H,	3.29;	N,	20.76.	Found:	C,	57.31;	H,	3.64;	N,	20.99%.	
	
2.2.5.	General	procedure	for	the	synthesis	of	compounds	
(10a,b)	and	(14a,b)	
	
A	 mixture	 of	 compound	 9	 or	 13	 (5	 mmol),	 ethyl	 iodide	
and/or	 benzyl	 bromide	 (5	 mmol)	 in	 ethanol	 (30	 mL)	 was	
refluxed	in	the	presence	of	anhydrous	sodium	acetate	(5	mmol)	
for	4	h.	The	solid	product	separated	from	the	hot	mixture	was	
filtered	off,	washed	with	water	and	recrystallized	from	ethanol	
to	afford	compounds	10a,b	(Scheme	2)	and	14a‐d	(Scheme	3),	
respectively.	
5‐(5‐(5‐(Ethylthio)‐1,3,4‐oxadiazol‐2‐yl)‐6‐methylpyridazin‐
3‐yl)quinolin‐8‐ol	 (10a):	 Color:	 Yellow.	 Yield:	 72%.	 M.p.:	 132‐
134	°C.	FT‐IR	(KBr,	ν,	cm−1):	2980	(CH‐	aliphatic),	1625	(C=N).	
1H	NMR	 (200	MHz,	DMSO‐d6,	 δ,	 ppm):	 1.20	 (t,	 J	=	7.4	Hz,	 3H,	
CH3),	2.99	(s,	3H,	CH3),	3.65	(q,	 J	=	7.4	Hz,	2H,	CH2),	7.18‐8.75	
(m,	7H,	5	Ar‐H,	CH‐pyridazine,	OH).	13C	NMR	(100	MHz,	DMSO‐
d6,	 δ,	 ppm):	 162.3,	 154.4,	 151.2,	 146.2,	 138.0,	 130.4,	 127.8,	
125.5,	 124.4,	 123.2,	 120.0,	 115.7,	 113.7,	 112.3,	 111.19,	 28.6,	
18.4,	 15.9.	 Anal.	 calcd.	 for	 C18	 H15N5O2S:	 C,	 59.16;	 H,	 4.14;	 N,	
19.17.	Found:	C,	59.49;	H,	3.51;	N,	19.49%.	
5‐{5‐[5‐(Benzyl	 sulfanyl)‐1,3,4‐oxadiazol‐2‐yl]‐6‐methylpyri	
dazin‐3‐yl}quinolin‐8‐ol	 (10b):	Color:	Yellow.	Yield:	65%.	M.p.:	
147‐149	 °C.	 FT‐IR	 (KBr,	 ν,	 cm−1):	 2980	 (CH‐	 aliphatic),	 1625	
(C=N).	1H	NMR	(200	MHz,	DMSO‐d6,	δ,	ppm):	3.03	(s,	3H,	CH3),	
4.15	 (s,	 2H,	 CH2),	 6.99‐8.88	 (m,	 12H,	 10	 Ar‐H,	 CH‐pyridazine,	
OH).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	161.7,	155.0,	150.5,	
148.8,	 137.5,	 129.1,	 128.3,	 127.5,	 126.2,	 125.3,	 124.6,	 123.7,	
122.1,	 120.2,	 120.0,	 119.6,	 118.4,	 116.7,	 115.6,	 115.3,	 113.4,	
36.7,	 18.2.	 Anal.	 calcd.	 for	 C23	 H17N5O2S:	 C,	 64.62;	 H,	 4.01;	 N,	
16.38.	Found:	C,	64.83;	H,	4.35;	N,	16.66%.	
5‐(5‐(5‐(Ethylthio)‐4‐phenyl‐4H‐1,2,4‐triazol‐3‐yl)‐6‐methyl	
pyridazin‐3‐yl)quinolin‐8‐ol	 (14a):	 Color:	 Yellow.	 Yield:	 79%.	
M.p.:	 170‐172	 °C.	 FT‐IR	 (KBr,	 ν,	 cm−1):	 2900	 (CH‐aliphatic),	
1625	(C=N),	1360	(C=S).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
1.31	(t,	J	=	7.4	Hz,	3H,	CH3),	2.80	(s,	3H,	CH3),	3.85	(q,	J	=	7.4	Hz,	
2H,	CH2),	6.85‐8.60	 (m,	 12H,	10	Ar‐H,	CH‐pyridazine,	OH).	 13C	
NMR	(100	MHz,	DMSO‐d6,	 δ,	ppm):	157.6,	156.2,	153.4,	149.0,	
148.4,	 140.6,	 138.1,	 136.6,	 130.9,	 130.1,	 129.5,	 128.3,	 127.0,	
126.7,	 126.1,	 125.9,	 123.5,	 120.2,	 116.7,	 113.3,	 112.7	 ,	 30.3,	
18.2,	 15.2.	 Anal.	 calcd.	 for	 C24H20N6OS:	 C,	 65.44;	 H,	 4.58;	 N,	
19.08.	Found:	C,	65.74;	H,	4.93;	N,	19.35%.	
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Scheme	2
	
	
5‐(5‐(5‐(Benzylthio)‐4‐phenyl‐4H‐1,2,4‐triazol‐3‐yl)‐6‐	
methylpyridazin‐3‐yl)quinolin‐8‐ol	 (14b):	 Color:	 Yellow.	 Yield:	
61%.	 M.p.:	 188‐190	 °C.	 FT‐IR	 (KBr,	 ν,	 cm−1):	 2950	 (CH‐
aliphatic),	1625	(C=N),	1420	(C=S).	1H	NMR	(400	MHz,	DMSO‐
d6,	 δ,	 ppm):	 3.10	 (s,	 3H,	 CH3),	 3.90	 (s,	 2H,	 CH2),	 7.01‐8.85	 (m,	
17H,	15	Ar‐H,	CH‐pyridazine,	OH).	Anal.	calcd.	 for	C29H22N6OS:	
C,	69.30;	H,	4.41;	N,	16.72.	Found:	C,	69.56;	H,	4.73;	N,	16.97%.	
	
2.2.6.	General	procedure	for	the	synthesis	of	compounds	
(11a‐d)	and	(15a‐d)	
	
Formalin	 40%	 (1.5	mL,	 20	mmol)	was	 added	 to	 a	 stirred	
solution	of	 compound	9	or	13	 (20	mmol)	 in	 absolute	 ethanol	
(40	 mL).	 An	 ethanolic	 solution	 (10	 mL)	 of	 the	 appropriate	
amine	 (20	 mmol)	 was	 added	 portion	 wise	 to	 the	 reaction	
mixture,	stirred	for	3	h	at	room	temperature,	and	left	overnight	
in	 a	 refrigerator.	 The	precipitate	 formed	was	filtered,	washed	
with	cold	ethanol,	dried,	and	crystallized	from	ethanol	to	afford	
compounds	 11a‐d	 (Scheme	 2)	 and	 15a‐d	 (Scheme	 3),	
respectively.	
5‐[6‐(8‐Hydroxyquinolin‐5‐yl)‐3‐methylpyridazin‐4‐yl]‐3‐
[(morpholino)methyl]‐1,3,4‐oxadiazole‐2(3H)‐thione	 (11a):	
Color:	 Yellow.	 Yield:	 60%.	 M.p.:	 187‐189	 °C.	 FT‐IR	 (KBr,	 ν,	
cm−1):	 2990	 (CH‐aliphatic),	 1625	 (C=N),	 1350	 (C=S).	 1H	 NMR	
(200	MHz,	DMSO‐d6,	δ,	ppm):	2.99	(s,	3H,	CH3),	3.15	(t,	 J	=	7.4	
Hz,	4H,	2CH2),	3.65	 (t,	 J	=	7.4	Hz,	4H,	2CH2),	5.12	(s,	2H,	CH2),	
7.25‐8.78	 (m,	 7H,	 5	 Ar‐H,	 CH‐pyridazine,	 OH).	 13C	 NMR	 (100	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 178.8,	 158.7,	 155.6,	 150.9,	 146.3,	
139.5,	 130.3,	 127.6,	 126.3,	 125.2,	 124.7,	 122.3,	 116.4,	 114.8,	
112.9,	 70.1,	 66.4,	 53.6,	 18.1.	 Anal.	 calcd.	 for	 C21	 H20N6O3S:	 C,	
57.79;	H,	4.62;	N,	19.25.	Found:	C,	58.11;	H,	4.99;	N,	19.60%.	
5‐[6‐(8‐Hydroxyquinolin‐5‐yl)‐3‐methylpyridazin‐4‐yl]‐3‐
[(phenylamino)methyl]‐1,3,4‐oxadiazole‐2(3H)‐thione	 (11b):	
Color:	Pale	yellow.	Yield:	59%.	M.p.:	208‐210	°C.	FT‐IR	(KBr,	ν,	
cm−1):	 3235	 (NH),	 2990	 (CH‐aliphatic),	 1635	 (C=N),	 1360	
(C=S).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	2.85	(s,	3H,	CH3),	
5.18	(s,	1H,	NH),	5.45	(d,	J	=	7.4	Hz,	2H,	CH2),	6.95‐8.75	(m,	12H,	
10	 Ar‐H,	 CH‐pyridazine,	 OH).	 Anal.	 calcd.	 for	 C23	 H18N6O2S:	 C,	
62.43;	H,	4.10;	N,	18.99.	Found:	C,	62.75;	H,	4.38;	N,	19.36%.	
5‐[6‐(8‐Hydroxyquinolin‐5‐yl)‐3‐methylpyridazin‐4‐yl]‐3‐[(4‐
methoxyphenylamino)methyl]‐1,3,4‐oxadiazole‐2(3H)‐thione	
(11c):	Color:	Yellow.	Yield:	64%.	M.p.:	172‐174	°C.	FT‐IR	(KBr,	
ν,	 cm−1):	 3330	 (NH),	 2990	 (CH‐aliphatic),	 1630	 (C=N),	 1377	
(C=S),	1236	(C‐O).	
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1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 2.95	 (s,	 3H,	 CH3),	
3.79	(s,	3H,	OCH3),	5.30	(d,	J	=	7.4	Hz,	2H,	CH2),	5.85	(s,	1H,	NH),	
6.85‐8.80	(m,	11H,	9	Ar‐H,	CH‐pyridazine,	OH).	Anal.	calcd.	for	
C24	 H20N6O3S:	 C,	 61.01;	 H,	 4.27;	 N,	 17.79.	 Found:	 C,	 61.45;	 H,	
4.63;	N,	18.09%.	
5‐(6‐(8‐Hydroxyquinolin‐5‐yl)‐3‐methylpyridazin‐4‐yl)‐3‐
((pyridin‐2‐ylamino)methyl)‐1,3,4‐oxadiazole‐2(3H)‐thione	
(11d):	Color:	Yellow.	Yield:	81%.	M.p.:	159‐161	°C.	FT‐IR	(KBr,	
ν,	 cm−1):	 3245	 (NH),	 2880	 (CH‐aliphatic),	 1630	 (C=N),	 1360	
(C=S).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	3.05	(s,	3H,	CH3),	
5.30	(s,	1H,	NH),	5.55	(d,	J	=	7.4	Hz,	2H,	CH2),	6.95‐8.90	(m,	11H,	
9	 Ar‐H,	 CH‐pyridazine,	 OH).	 Anal.	 calcd.	 for	 C22H17N7O2S:	 C,	
59.58;	H,	3.86;	N,	22.11.	Found:	C,	59.92;	H,	3.83;	N,	22.45%.	
3‐(6‐(8‐Hydroxyquinolin‐5‐yl)‐3‐methylpyridazin‐4‐yl)‐1‐
(morpholinomethyl)‐4‐phenyl‐1H‐1,2,4‐triazole‐5(4H)‐thione	
(15a):	Color:	Yellow.	Yield:	62%.	M.p.:	197‐199	°C.	FT‐IR	(KBr,	
ν,	cm−1):	2995,	2890	(CH‐aliphatic),	1620	C=N),	1340	(C=S).	1H	
NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	2.78	(s,	3H,	CH3),	3.65	(t,	J	=	
7.4	Hz,	4H,	2CH2),	3.70	(t,	J	=	7.4	Hz,	4H,	2CH2),	5.20	(s,	2H,	CH2),	
7.05‐8.85	(m,	12H,	10	Ar‐H,	CH‐pyridazine,	OH).	Anal.	calcd.	for	
C27	 H25N7O2S:	 C,	 63.39;	 H,	 4.93;	 N,	 19.16.	 Found:	 C,	 63.59;	 H,	
5.02;	N,	19.44%.	
3‐(6‐(8‐Hydroxyquinolin‐5‐yl)‐3‐methylpyridazin‐4‐yl)‐4‐
phenyl‐1‐((phenylamino)methyl)‐1H‐1,2,4‐triazole‐5(4H)‐thione	
(15b):	Color:	Yellow.	Yield:	55%.	M.p.:	275‐277	°C.	FT‐IR	(KBr,	
ν,	 cm−1):	 3320	 (NH),	 2990,	 2895	 (CH‐aliphatic),	 1620	 (C=N),	
1330	(C=S).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	2.80	(s,	3H,	
CH3),	5.20	 (s,	 1H,	NH),	5.60	 (d,	 J	=	7.4	Hz,	2H,	CH2),	6.90‐8.80	
(m,	 17H,	 15	 Ar‐H,	 CH‐pyridazine,	 OH).	 13C	 NMR	 (100	 MHz,	
DMSO‐d6,	 δ,	 ppm):	 165.5,	 159.4,	 158.8,	 157.2,	 155.5,	 154.3,	
150.6,	 148.1,	 146.4,	 144.7,	 140.8,	 139.5,	 138.7,	 136.4,	 130.3,	
128.2,	 127.3,	 126.5,	 125.4,	 124.8,	 122.3,	 117.5,	 116.7,	 114.8,	
113.3,	112.1,	‐111.5,	71.6,	18.6.	Anal.	calcd.	 for	C29	H23N7OS:	C,	
67.29;	H,	4.48;	N,	18.94.	Found:	C,	67.45;	H,	4.81;	N,	19.19%.	
3‐(6‐(8‐Hydroxyquinolin‐5‐yl)‐3‐methylpyridazin‐4‐yl)‐1‐
(((4‐methoxyphenyl)amino)methyl)‐4‐phenyl‐1H‐1,2,4‐triazole‐
5(4H)‐thione	(15c):	Color:	Yellow.	Yield:	71%.	M.p.:	231‐233	°C.	
FT‐IR	 (KBr,	 ν,	 cm−1):	 3330	 (NH),	 2990,	 2895	 (CH‐aliphatic),	
1630	(C=N),	1330	(C=S).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
2.90	(s,	3H,	CH3),	3.80	(s,	3H,	OCH3),	4.95	(s,	1H,	NH),	5.65	(d,	J	=	
7.4	 Hz,	 2H,	 CH2),	 6.95‐8.85	 (m,	 16H,	 14	 Ar‐H,	 CH‐pyridazine,	
OH).	Anal.	 calcd.	 for	 C30	H25N7O2S:	 C,	 65.80;	H,	 4.60;	N,	 17.90.	
Found:	C,	65.95;	H,	4.71;	N,	18.12%.	
	
Abdelmohsen	/	European	Journal	of	Chemistry	5	(3)	(2014)	517‐525	 521	
 
	
CH
2 (CO
O
Et)2
Fusion
anh.NaOAc/ AcOH
 
	
Scheme	4
	
	
3‐(6‐(8‐Hydroxyquinolin‐5‐yl)‐3‐methylpyridazin‐4‐yl)‐4‐
phenyl‐1‐((pyridin‐2‐ylamino)methyl)‐1H‐1,2,4‐triazole‐5(4H)‐
thione	(15d):	Color:	Yellow.	Yield:	78%.	M.p.:	280‐282	°C.	FT‐IR	
(KBr,	 ν,	 cm−1):	 3280	 (NH),	 2990,	 3000	 (CH‐aliphatic),	 1625	
(C=N),	1345	(C=S).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	2.85	
(s,	3H,	CH3),	5.75	(s,	2H,	CH2),	6.80‐8.80	(m,	16H,	14	Ar‐H,	CH‐
pyridazine,	OH),	9.90	(s,	1H,	NH).	Anal.	calcd.	for	C28	H22N8OS:	C,	
64.85;	H,	4.28;	N,	21.61.	Found:	C,	65.11;	H,	4.43;	N,	21.88%.	
	
2.2.7.	Synthesis	of	2‐(6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methyl	
pyridazine‐4‐carbonyl)‐N‐phenylhydrazinecarbothioamide	
(12)	
	
A	 mixture	 of	 hydrazide	 (8)	 (1.48	 g,	 5	 mmol)	 and	 phenyl	
isothiocyanate	 (0.65	 g,	 5	mmol)	 in	 30	mL	 of	 absolute	 ethanol	
were	refluxed	on	a	steam	bath	for	1	h.	The	resulting	solid	was	
filtered	and	recrystallized	from	the	methanol	to	give	compound	
12	(Scheme	3).	Color:	Pale	yellow.	Yield:	72%.	M.p.:	221‐223	°C.	
FT‐IR	 (KBr,	 ν,	 cm−1):	 3315,	 3270,	 3190	 (3NH),	 2987	 (CH‐
aliphatic),	1674	(C=O),	1325	(C=S).	1H	NMR	(400	MHz,	DMSO‐
d6,	δ,	ppm):	2.88	(s,	3H,	CH3),	6.85‐8.80	(m,	12H,	10	Ar‐H,	CH‐
pyridazine,	OH),	9.25	(S,	1H,	NH),	9.85	(s,	1H,	NH),	10.35	(s,	1H,	
NH).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	187.2,	166.1,	159.3,	
153.3,	 149.2,	 148.7,	 145.2,	 138.7,	 130.1,	 129.1,	 126.6,	 125.6,	
125.0,	 124.9,	 123.8,	 120.3,	 118.5,	 115.3,	 113.2,	 112.4,	 112.9,	
18.5.	Anal.	 calcd.	 for	C22	H18N6O2S:	C,	 61.38;	H,	4.21;	N,	19.52.	
Found:	C,	61.70;	H,	4.58;	N,	19.88%.	
	
2.2.8.	Synthesis	of	5‐[6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methyl	
pyridazin‐4‐yl]‐4‐phenyl‐2,4‐dihydro‐3H‐1,2,4‐triazole‐3‐
thione	(13)	
	
A	suspension	of	thiosemicarbazide	(12)	(1.3	g,	3	mmol)	in	
sodium	 hydroxide	 solution	 (5%,	 25	 mL)	 was	 heated	 under	
reflux	 for	 1	 h.	 The	 reaction	mixture	was	 allowed	 to	 cool	 and	
then	 adjusted	 to	 pH	 6	 with	 10%	 hydrochloric	 acid.	 The	
precipitate	formed	was	filtered,	washed	with	water,	dried,	and	
recrystallized	from	methanol	to	give	compound	13	(Scheme	3).	
Color:	White.	Yield:	66%.	M.p.:	165‐167	°C.	FT‐IR	(KBr,	ν,	cm−1):	
3170	(NH),	1625	(C=N),	1395	(C=S).	1H	NMR	(400	MHz,	DMSO‐
d6,	δ,	ppm):	2.69	(s,	3H,	CH3),	6.85‐8.85	(m,	12H,	10	Ar‐H,	CH‐
pyridazine,	OH),	13.67	(S,	1H,	NH).	Anal.	calcd.	for	C22	H16N6OS:	
C,	64.06;	H,	3.91;	N,	20.38.	Found:	C,	64.38;	H,	4.22;	N,	20.70%.	
	
2.2.9.	Synthesis	of	2‐{[6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methyl	
pyridazin‐4‐yl]carbonyl}‐5‐methyl‐2,4‐dihydro‐3H‐pyrazol‐
3‐one	(16)	
	
Ethyl	acetoacetate	(0.39	g,	3	mmol)	was	added	to	a	solution	
of	the	acid	hydrazide	(8)	(0.59	g,	2	mmol)	 in	absolute	ethanol	
(15	mL),	and	the	reaction	mixture	was	heated	under	reflux	for	
10	 h.	 Solvent	 was	 removed	 under	 reduced	 pressure	 and	 the	
remaining	residue	was	recrystallized	 from	aqueous	ethanol	 to	
give	compound	16	(Scheme	4).	
	
2.2.10.	Synthesis	of	(3,5‐dimethyl‐1H‐pyrazol‐1‐yl)[6‐(8‐
hydroxyquinolin‐5‐yl)3‐methylpyridazin‐4‐yl]methanone	
(17)	
	
To	 a	 solution	 of	 compound	 8	 (0.59	 g,	 2	 mmol)	 in	 glacial	
acetic	acid	 (15	mL),	was	added	acetylacetone	 (0.2	g,	2	mmol).	
The	reaction	mixture	was	heated	under	reflux	for	8	h,	and	then	
allowed	 to	 cool	 to	 room	 temperature.	 The	 solid	 product	 thus	
formed	 was	 filtered,	 thoroughly	 washed	 with	 cold	 ethanol,	
dried	 and	 recrystallized	 from	 ethanol	 to	 give	 compound	 17	
(Scheme	4).	Color:	Pale	light.	Yield:	70%.	M.p.:	260‐262	°C.	FT‐
IR	(KBr,	ν,	cm−1):	2990	(CH‐aliphatic),	1700	(C=O),	1635	(C=N).	
1H	NMR	(200	MHz,	CDCl3,	δ,	ppm):	2.35	(s,	3H,	CH3),	2.40	(s,	3H,	
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CH3),	2.75	(s,	3H,	CH3),	6.15	(s,	1H,	CH‐pyrazole),	7.05‐8.80	(m,	
7H,	 5	 Ar‐H,	 CH‐pyridazine,	 OH).	 13C	 NMR	 (100	MHz,	 CDCl3,	 δ,	
ppm):	 166.2,	 159.2,	 150.7,	 148.3,	 140.5,	 137.6,	 134.8,	 130.5,	
129.0,	 128.4,	 125.1,	 124.3,	 123.6,	 122.9,	 115.8,	 113.7,	 112.5,	
102.9,	18.2,	17.8,	11.7.	Anal.	calcd.	 for	C20H17N5O2:	C,	66.84;	H,	
4.77;	N,	19.49.	Found:	C,	67.01;	H,	5.10;	N,	19.73%.	
	
2.2.11.	 Synthesis	 of	 1‐(6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methyl	
pyridazine‐4‐carbonyl)pyrazolidine‐3,5‐dione	(18)	
	
A	mixture	of	the	starting	compound	8	(0.59	g,	2	mmol)	and	
diethyl	malonate	(0.48	g,	3	mmol)	was	heated	at	200	°C	 in	an	
oil	 bath	 for	 2	 h.	 After	 being	 cooled	 to	 room	 temperature,	 the	
solidified	product	was	treated	with	cold	diethyl	ether,	filtered,	
washed	 with	 diethyl	 ether,	 dried	 and	 recrystallized	 from	
aqueous	ethanol	to	give	compound	18	(Scheme	4).	Color:	Pale	
light.	Yield:	48%.	M.p.:	241‐243	 °C.	FT‐IR	 (KBr,	 ν,	 cm−1):	3250	
(NH),	 1720	 (C=O),	 1700	 (C=O),	 1675	 (C=O),	 1620	 (C=N).	 1H	
NMR	(200	MHz,	CDCl3,	δ,	ppm):	2.79	 (s,	3H,	CH3),	3.50	 (s,	2H,	
CH2),	 7.05‐8.80	 (m,	7H,	 5	Ar‐H,	CH‐	pyridazine,	OH),	10.35	 (s,	
1H,	NH).	Anal.	calcd.	for	C18	H13N5O4:	C,	59.50;	H,	3.61;	N,	19.28.	
Found:	C,	59.82;	H,	3.85;	N,	19.43%.	
	
2.2.12.	General	procedure	for	the	synthesis	of	compounds	
(19a‐c)	
	
A	mixture	of	 compound	8	 (10	mmol)	 and	 the	appropriate	
aromatic	 aldehyde	 (10	 mmol)	 was	 stirred	 under	 reflux	 in	
ethanol	(30	mL)	in	the	presence	of	a	few	drops	of	piperidine	for	
5	 h.	 The	 reaction	 mixture	 was	 allowed	 to	 cool	 to	 room	
temperature,	 poured	 into	water,	whereby	 a	 solid	 formed	 that	
was	 filtered	 off	 and	 crystallized	 from	 an	 appropriate	 solvent	
(Scheme	4).	
6‐(8‐Hydroxyquinolin‐5‐yl)‐N'‐[phenylmethylidene]‐3‐methyl	
pyridazine‐4‐carbohydrazide	 (19a):	 Color:	 Pale	 white	 from	
acetic	acid.	Yield:	66%.	M.p.:	255‐257	°C.	FT‐IR	(KBr,	ν,	 cm−1):	
3425	(NH),	1675	(C=O),	1625	(C=N).	1H	NMR	(400	MHz,	DMSO‐
d6,	δ,	ppm):	2.85	(s,	3H,	CH3),	6.90‐8.70	(m,	12H,	10	Ar‐H,	CH‐
pyridazine,	OH),	8.95	(s,	1H,	CH‐azomethine),	11.10	(s,	1H,	NH	
D2O‐exchangeable).	 Anal.	 calcd.	 for	 C22H17N5O2:	 C,	 68.92;	 H,	
4.47;	N,	18.27.	Found:	C,	69.16;	H,	4.63;	N,	18.41%.	
6‐(8‐Hydroxyquinolin‐5‐yl)‐N'‐[4‐chlorophenylmethylidene]‐
3‐methylpyridazine‐4‐carbohydrazide	 (19b):	 Color:	 Pale	 light	
yellow	from	dioxane.	Yield:	60%.	M.p.:	266‐268	°C.	FT‐IR	(KBr,	
ν,	 cm−1):	 3320	 (NH),	 1685	 (C=O),	 1640	 (C=N).	 1H	 NMR	 (400	
MHz,	DMSO‐d6,	δ,	ppm):	2.77	(s,	3H,	CH3),	6.95‐8.65	(m,	11H,	9	
Ar‐H,	 CH‐pyridazine,	OH),	 9.15	 (s,	 1H,	 CH	azomethene),	 11.25	
(s,	 1H,	NH	D2O‐exchangeable).	MS	 (EI,	m/z	 (%)):	 417.84	 (M+.,	
61).	 Anal.	 calcd.	 for	 C22H16ClN5O2:	 C,	 63.24;	 H,	 3.86;	 N,	 16.76.	
Found:	C,	63.58;	H,	4.09;	N,	18.98%.	
6‐(8‐Hydroxyquinolin‐5‐yl)‐N'‐[4‐methoxyphenyl	 methylide	
ne]‐3‐methyl	 pyridazine‐4‐carbohydrazide	 (19c):	 Color:	 Pale	
white	from	dioxane.	Yield:	59%.	M.p.:	310‐312	°C.	FT‐IR	(KBr,	ν,	
cm−1):	 3330	 (NH),	 1690	 (C=O),	 1630	 (C=N),	 1230	 (C‐O).	 1H	
NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	2.82	(s,	3H,	CH3),	3.95	(s,	3H,	
OCH3),	7.01‐8.77	(m,	11H,	9	Ar‐H,	CH‐pyridazine,	OH),	9.44	(s,	
1H,	CH‐azomethene),	10.65	(s,	1H,	NH	D2O‐exchangeable).	Anal.	
calcd.	 for	 C23H19N5O3:	 C,	 66.82;	 H,	 4.63;	 N,	 16.94.	 Found:	 C,	
67.03;	H,	4.99;	N,	17.11%.	
	
2.2.13.	Synthesis	of	6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methyl‐N'‐
[2‐oxo‐1,2‐dihydro‐3H‐indol‐3‐ylidene]pyridazine‐4‐carbo	
hydrazide	(20)	
	
A	 solution	of	 the	acid	hydrazide	 (8)	 (0.59	g,	 2	mmol)	 and	
isatin	(0.29	g,	2	mmol)	in	glacial	acetic	acid	(10	mL)	was	heated	
under	 reflux	 for	 2	 h,	 during	 which	 a	 deep	 yellow	 solid	 was	
partially	crystallized	out.	The	solid	separated	upon	cooling	was	
filtered,	 washed	 with	 cold	 ethanol	 and	 recrystallized	 from	
ethanol	to	give	compound	20	(Scheme	4).	Color:	Yellow.	Yield:	
68%.	M.p.:	320‐322	°C.	FT‐IR	(KBr,	ν,	cm−1):	3310,	3225	(2NH),	
1675	(CO),	1660	(CO),	1630	(C=N).	1H	NMR	(200	MHz,	CDCl3,	δ,	
ppm):	 2.65	 (s,	 3H,	 CH3),	 6.85‐8.80	 (m,	 11H,	 9	 Ar‐H,	 CH‐
pyridazine,	OH),	9.15	(s,	1H,	NH),	9.33	(s,	1H,	NH).	Anal.	calcd.	
for	 C23H16N6O3:	 C,	 65.09;	H,	 3.80;	N,	 19.80.	 Found:C,	 65.26;	H,	
4.07;	N,	19.95%.	
	
2.2.14.	Synthesis	of	N‐(2,5‐dioxo‐2,5‐dihydro‐1H‐pyrrol‐1‐
yl)‐6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methylpyridazine‐4‐
carboxamide	(21)	
	
A	mixture	of	the	acid	hydrazide	(8)	(0.59	g,	2	mmol),	maleic	
anhydride	(0.2	g,	2	mmol)	and	anhydrous	sodium	acetate	(0.16	
g,	 2.5	mmol)	 in	 glacial	 acetic	 acid	 (15	mL)	was	 heated	 under	
reflux	 for	 10	 h.	 The	 reaction	 mixture	 was	 concentrated	 in	
vacuum	to	half	its	volume	and	allowed	to	cool.	The	precipitated	
solid	product	was	filtered,	washed	with	cold	ethanol,	dried	and	
recrystallized	 from	 acetic	 acid	 to	 give	 compound	21	 (Scheme	
4).	 Color:	 Yellow.	Yield:	 55%.	M.p.:	 173‐175	 °C.	 FT‐IR	 (KBr,	 ν,	
cm−1):	 3330	 (NH),	 1705,	 1680,	 1665	 (3C=O),	 1620	 (C=N).	 1H	
NMR	(200	MHz,	CDCl3,	δ,	ppm):	2.70	(s,	3H,	CH3),	6.40‐6.48	(m,	
2H,	olefinic‐CH),	7.15‐8.80	(m,	7H,	5	Ar‐H,	CH‐pyridazine,	OH),	
9.05	(s,	1H,	NH).	Anal.	calcd.	for	C19H13N5O4:	C,	60.80;	H,	3.49;	N,	
18.66.	Found:	C,	61.11;	H,	3.87;	N,	18.91%.		
	
2.3.	Antimicrobial	assay	
	
The	 antimicrobial	 activity	 of	 13	 selected	 compounds	 was	
evaluated	 against	 four	 bacterial	 and	 four	 fungal	 strains.	 All	
microbial	strains	were	kindly	provided	by	the	Assiut	University	
Mycological	 Centre	 (AUMC).	 These	 strains	 are	 common	
contaminants	of	 the	environment	 in	Egypt	and	some	of	which	
are	involved	human	and	animal	diseases	(Trichophyton	rubrum,	
Candida	 albicans,	 Geotrichum	 candidum,	 Scopulariopsis	 brevi‐
caulis,	Aspergillus	flavus),	plant	diseases	(Fusarium	oxysporum)	
or	frequently	reported	from	contaminated	soil,	water	and	food	
substances	 (Escherichia	 coli,	 Bacillus	 cereus,	 Pseudomonas	
aeruginosa,	 Serratia	 marcescens,	 Staphylococcus	 aureus,	
Micrococcus	 luteus)	 To	 prepare	 inocula	 for	 bioassay,	 bacterial	
strains	were	 individually	 cultured	 for	 48	h	 in	 100	mL	 conical	
flasks	 containing	 30	 mL	 nutrient	 broth	 medium.	 Fungi	 were	
grown	 for	 7	 days	 in	 100	 mL	 conicals	 containing	 30	 mL	
Sabouraud's	dextrose	broth.	Bioassay	was	done	in	10	cm	sterile	
plastic	Petri	plates	in	which	microbial	suspension	(1	mL/plate)	
and	 15	mL	 of	 appropriate	 agar	 medium	 (15	mL/plate)	 were	
poured.	 Nutrient	 agar	 and	 Sabouraud's	 dextrose	 agar	 were	
respectively	used	 for	bacteria	and	 fungi.	After	solidification	of	
the	media,	 5	mm	 diameter	 cavities	 were	 cut	 in	 the	 solidified	
agar	 (4	 cavities/plate)	 using	 sterile	 cork	 borer.	 The	 tested	
compounds	 were	 dissolved	 in	 dimethyl	 sulfuxide	 (DMSO)	 at	
2%w:v	 (20	 mg/mL),	 pipetted	 and	 poured	 in	 the	 cavities	 (20	
µL/cavity).	 Cultures	were	 then	 incubated	 at	 28	 °C	 for	 48	h	 in	
case	of	bacteria	and	up	to	7	days	in	case	of	fungi.	Results	were	
read	 as	 the	 diameter	 (in	 mm)	 of	 inhibition	 zone	 around	
cavities.	To	determine	the	minimum	inhibitory	concentrations	
(MICs),	 several	 concentrations	 in	 DMSO	 of	 the	 compounds	
under	testing	that	gave	positive	results,	have	been	prepared	in	
descending	manner	 down	 to	 a	 concentration	 of	 0.08	mg/mL.	
The	solutions	of	different	compounds	were	similarly	assayed	as	
mentioned	before	and	the	least	concentration	(below	which	no	
activity	was	observed)	was	recorded	as	the	MIC.	
	
3.	Results	and	discussion	
	
3.1.	Chemistry	
	
The	 starting	 compound	 (8‐hydroxyquinolin‐5‐yl)(oxo)	
acetaldehyde	(2)	was	prepared	from	the	well‐known	5‐acetyl‐
8‐hydroxyquinoline	(1)	via	oxidation	with	selenium	dioxide	in	
a	 mixture	 of	 dioxane	 and	 water	 according	 to	 the	 reported	
procedure	for	the	synthesis	of	aryglyoxal	[25].	
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Scheme	5
	
	
Multi‐compo‐nent	 reaction	 of	 compound	 2,	 ethyl	
acetoacetate	3	 and	 an	 excess	 amount	 of	 hydrazine	hydrate	 in	
water	 at	 room	 temperature	 afforded	 ethyl	 6‐(8‐hydroxy	
quinolin‐5‐yl)‐3‐methyl	 pyridazin‐4‐carboxylate	 (4)	 (Scheme	
1).	 The	 structure	 of	 synthesized	 compound	4	was	 established	
by	1H	NMR,	13C	NMR,	IR,	MS	spectroscopes	in	combination	with	
elemental	 analyses.	 In	 the	 1H	 NMR	 spectrum	 of	 compound	4,	
the	 CH‐pyridazine	 ring	 is	much	 deshielded	 and	 resonating	 at	
low	 field	 and	 appear	 at	 δ	 =	 8.3	 ppm.	 The	 mass	 spectrum	 of	
compound	4	showed	its	correct	parent	ion	peak	at	m/z	309.11	
(M+,	67%)	(Scheme	1).	
The	 suggested	 mechanism	 involves	 the	 attack	 of	 enolate	
structure	5	 onto	 the	glyoxal	2,	 then	 in	 situ	generated	ethyl	2‐
acetyl‐3‐hydroxy‐4‐(8‐hydroxyquinolin‐5‐yl)‐4‐oxobutanoate	
(6),	in	the	presence	of	NH2NH2,	converts	to	compound	7	which	
then	 loses	 three	H2O	molecules	 to	 afford	 the	 target	product	4	
(Scheme	5).		
Treatment	of	compound	4	with	hydrazine	hydrate	leads	to	
the	formation	of	the	corresponding	carbohydrazide	8.	Because	
of	 the	 broad	 utility	 of	 heterocyclization	 carbohydrazides	 as	
intermediates	 for	 the	 synthesis	 of	 several	 systems	 containing	
oxadiazole	and	triazole	nuclei	[26],	6‐(8‐hydroxyquinolin‐5‐yl)‐
3‐methylpyridazine‐4‐carbohydrazide	 (8)	 was	 used	 in	 prepa‐
ring	 a	 new	 series	 of	 heterocyclic	 compounds.	 The	 reaction	 of	
compound	8	with	carbon	disulphide	in	the	presence	of	ethanol	
solution	of	potassium	hydroxide	gave	 the	mercaptooxadiazole	
derivative	 9.	 The	 later	 was	 easily	 converted	 into	 the	 corres‐
ponding	 s‐alkylated	 products	 10a	 and	 10b	 upon	 treatment	
with	 ethyl	 iodide	 and/or	 benzyl	 bromide,	 respectively.	 The	
interaction	 of	 compound	 9	 with	 formaldehyde	 and	 some	
different	 primary	 and	 secondary	 amines	 afforded	 the	 corres‐
ponding	Mannich	bases	11a‐d.	The	IR	spectrum	of	compound	9	
revealed	the	characteristic	band	at	1437	cm‐1	corresponding	to	
the	thione	(C=S)	function.	The	1H	NMR	spectrum	of	compound	
11a	 (R	 =	 Morpholine)	 displayed	 a	 singlet	 signal	 due	 to	 CH2	
protons	at	5.12	ppm.	Whereas,	compounds	11b‐d	(R	=	Primary	
aromatic	 and	 heterocyclic	 amine)	 displayed	 a	 doublet	 signals	
ranged	 at	 5.45‐5.55	 ppm	 corresponding	 to	 CH2	 protons	
(Scheme	2).		
On	the	other	hand,	compound	8	when	allowed	to	react	with	
phenyl	isothiocyanate	in	ethanol,	it	gave	the	thiosemicarbazide	
derivative	(12).	Heating	of	compound	12	in	an	aqueous	sodium	
hydroxide	 solution	 (5%)	 yielded	 5‐[6‐(8‐hydroxyquinolin‐5‐
yl)‐3‐methylpyridazin‐4‐yl]‐4‐phenyl‐2,4‐dihydro‐3H‐1,2,4‐tri	
azole‐3‐thione	 (13).	 The	 later	 was	 converted	 into	 the	 corres‐
ponding	 s‐alkylated	 triazolo	 products	 14a	 and	 14b	 upon	
treatment	with	ethyl	iodide	and	/or	benzyl	bromide	in	ethanol	
in	 the	 presence	 of	 anhydrous	 sodium	 acetate.	 Mannich	 bases	
(15a‐d)	 were	 obtained	 from	 compound	 13	 using	 the	 former	
procedure	for	producing	compounds	11a‐d	(Scheme	3).		
The	synthesis	of	the	target	compounds	16‐21	is	depicted	in	
Scheme	 4,	 in	 which	 the	 starting	 compound	 6‐(8‐hydroxy‐
quinolin‐5‐yl)‐3‐methylpyridazine‐4‐carbohydrazide	 (8)	 was	
allowed	to	react	with	ethyl	acetoacetate	 in	ethanol	 to	produce	
the	 pyrazolinone	 derivative	 (16).	 Condensing	 of	 compound	8	
with	 acetyl	 acetone	 in	 glacial	 acetic	 acid	 gave	 rise	 to	 the	
corresponding	 (3,5‐dimethyl‐1H‐pyrazol‐1‐yl)[6‐(8‐hydroxy	
quinolin‐5‐yl)3‐methylpyridazin‐4‐yl]methanone	(17).	
Whereas,	 heating	 the	 same	 acid	 hydrazide	8	 with	 diethyl	
malonate	 at	 200	 °C	 afforded	 the	 targeted	 1‐(6‐(8‐hydroxy	
quinolin‐5‐yl)‐3‐methylpyridazine‐4‐carbonyl)	 pyrazolidine‐
3,5‐dione	 (18).	 The	 azomethine	 derivatives	 19a‐19c	 and	 20	
were	 obtained	 upon	 treatment	 of	 compound	8	with	 aromatic	
aldehydes	 in	refluxing	ethanol	 in	presence	of	catalytic	amount	
of	piperidine	 and/or	 condensing	of	 the	 acid	hydrazide	5	with	
isatin	in	glacial	acetic	acid,	respectively.	On	the	other	hand,	(8‐
hydroxyquinolin‐5‐yl)pyridazine	scaffold	was	allowed	to	link	to	
a	nitrogenous	heterocyclic	ring	system	through	a	carboxamide	
functionality.	 Thus,	 compound	 8	 when	 reacted	 with	 maleic	
anhydride	 in	 glacial	 acetic	 acid	 in	 the	 presence	 of	 anhydrous	
sodium	 acetate,	 it	 produced	 N‐(2,5‐dioxo‐2,5‐dihydro‐1H‐
pyrrol‐1‐yl)‐6‐(8‐hydroxyquinolin‐5‐yl)‐3‐methylpyridazine‐4‐
carboxamide	(21)	(Scheme	4).		
	
3.2.	Biological	studies	
	
3.2.1.	In	vitro	antibacterial	activity	
	
Using	 agar	 well‐diffusion	 method	 [27],	 thirteen	 selected	
derivatives	(4,	8,	9,	10a,	11b,	11c,	12,	13,	14a,	14b,	15b,	15c	
and	19b)	were	screened	against	Staphylococcus	aureus	(AUMC	
B.54)	 and	 Bacillus	 cereus	 (AUMC	 B.52)	 as	 Gram	 positive	
bacteria	 and	 Escherichia	 coli	 (AUMC	 B.53)	 and	 Pseudomonas	
aeruginosa	 (AUMC	 B.73)	 as	 Gram	 negative	 bacteria	 using	
Chloramphenicol	as	control	 (in	a	 concentration	of	20	mg/mL)	
(Table	1).	
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Table	1.	Antibacterial	activity	of	some	5‐pyridazinyl‐8‐quinolinol	derivatives	(20	mg/mL).	
Compound	 Diameter	of	growth	of	inhibition	zone	(mm)	*	 	
Staphylococcus	aureus	
AUMC.B‐54	
Bacillus	cereus
AUMC.B‐52
Escherichia	coli
AUMC.B‐53
Pseudomonas	aeruginosa
AUMC.B‐73	
4	 ‐	 6 8 ‐	
8	 20	 24 25 ‐	
9	 ‐	 ‐ ‐ ‐	
10a	 16	 30 33 ‐	
11b	 ‐	 5 ‐ ‐	
11c	 ‐	 ‐ 26 30	
12	 ‐	 ‐	 ‐	 ‐	
13	 24	 34	 ‐	 ‐	
14a	 ‐	 ‐	 7	 ‐	
14b	 26	 25	 33	 23	
15b	 18	 29 26 23	
15c	 22	 32 ‐ ‐	
19b	 ‐	 5 ‐ 7	
Chloramphenicol	 18	 23 21 19	
*	The	amount	added	in	each	pore	is	50	μL,	AUMC	=	Assiut	University	Mycological	Center.	
	
	
Table	2.	Antibacterial	activity	data.	
Compound	 Diameter	of	growth	of	inhibition	zone	(mm)*	MIC	(mg/mL)	 	
Staphylococcus	aureus	
AUMC.B‐54	
Bacillus	cereus
AUMC.B‐52	
Escherichia	coli
AUMC.B‐53	
Pseudomonas	aeruginosa
AUMC.B‐73	
8	 18	(2.5)	 18	(2.5) 12	(1.25) ‐	
10a	 10	(5)	 16	(5) 10	(0.15) ‐	
11c	 ‐	 ‐ 10(1.25) 9	(0.3)	
13	 9	(0.3)	 11(2.5) ‐ ‐	
14b	 13	(0.3)	 8	(1.25) 11	(1.25) 9	(0.6)	
15b	 8(0.25)	 10	(0.3) 8	(2.5) 10	(0.3)	
15c	 13	(5)	 10	(0.3)	 ‐	 ‐	
Chloramphenicol	 10	(0.08)	 12	(1.25)	 10	(0.07)	 12	(0.3)	
	
	
The	 results	 were	 recorded	 for	 each	 tested	 compound	 as	
average	 diameter	 of	 zone	 of	 inhibition	 of	 bacterial	 growth	 in	
millimeters.	Minimum	inhibitory	concentration	(MIC)	measure‐
ments	were	performed	using	agar	well	diffusion	method	(Table	
2).	 MIC	 of	 those	 compounds	 was	 determined	 which	 were	
showing	 activity	 in	 primary	 screening.	 The	 results	 of	
preliminary	 antibacterial	 testing	 of	 selected	 compounds	 are	
shown	in	Table	1	revealed	that	only	seven	compounds	8,	10a,	
11c,	 13,	 14b,	 15b	 and	 15c	 possessed	 moderate	 to	 excellent	
antibacterial	 activity	 against	 both	 Gram‐positive	 and	 Gram‐
negative	 bacteria.	 It	 was	 found	 that	 conversion	 of	 4‐ethoxy	
group	 in	 compound	4	 with	 carbohydrazide	 one	 compound	8,	
contribute	 to	 a	 good	 potency	 towards	 Gram‐positive	 bacteria	
Staphylococcus	 aureus,	 Bacillus	 cereus	 and	 against	 Gram‐
negative	 bacteria	 Escherichia	 coli	 only	 (zones	 of	 inhibition	
range	 from	 20	 to	 25	 mm)	 and	 with	 minimum	 inhibitory	
concentrations	 (MIC)	 range	 between	 2.5	 and	 1.25	 mg/mL.	
Construction	 of	 an	 thiooxadiazole	 ring	 compound	 9,	 did	 not	
display	 any	 antibacterial	 activity.	Whereas,	 the	 ethyl	 thiooxa‐
diazole	 derivative	 compound	 10a,	 exhibited	 a	 remarkable	
antibacterial	 activity	 against	 both	 Gram‐positive	 and	 Gram‐
negative	bacteria	except	towards	Pseudomonas	aeruginosa	with	
0.15	 mg/mL	 of	 MIC	 against	 Escherichia	 coli.	 However,	 the	
substituted‐3‐aminooxadiazole	 derivative	 with	 an	 electron	
donating	methoxy	group	(11c)	was	more	potent	against	Gram‐
negative	 bacteria	 (Escherichia	 coli	 and	 Pseudomonas	 aerugi‐
nosa)	 zones	 of	 inhibition	 range	 from	26	 to	 30	mm,	while	 the	
non‐substituted	one	compound	11b	was	inactive.	Construction	
of	 an	 thiotriazole	 ring	 compound	 13	 displayed	 a	 remarkable	
activity	 against	 Gram‐positive	 bacteria	 Staphylococcus	 aureus,	
Bacillus	cereus	only.	The	ethyl	triazolethiol	derivative	(14a)	did	
not	show	any	activity.	Whereas,	 the	benzyl	one	(14b)	 is	more	
potent	against	both	Gram‐positive	and	Gram‐negative	bacteria	
with	0.3	mg/mL	of	MIC	against	Staphylococcus	aureus.	Among	
the	 Mannich	 bases	 15b	 and	 15c,	 compound	 15b	 with	 non‐
substituted	phenyl	group	showed	highest	activity	against	both	
Gram‐positive	 and	 Gram‐negative	 bacteria	 with	 minimum	
inhibitory	 concentrations	 (MIC)	 range	 between	 0.25	 and	 2.5	
mg/mL.	 Whereas,	 the	 derivative	 15c	 with	 an	 electron	 with‐
drawing	 group	 exhibited	 only	 a	 good	 activity	 against	 Gram‐
positive	bacteria	Staphylococcus	aureus,	Bacillus	cereus	only.	 It	
should	be	noted	that	Schiff	bases	with	an	electron	withdrawing	
chlorine	atom	compound	19b	did	not	exihibit	any	antibacterial	
activity	towards	the	tested	bacteria	(Table	2).		
	
3.2.2.	In	vitro	antifungal	activity	
	
The	same	thirteen	selected	derivatives	compounds	(4,	8,	9,	
10a,	 11b,	 11c,	 12,	 13,	 14a,	 14b,	 15b,	 15c	 and	 19b)	 were	
screened	 for	 their	 antifungal	 activities	 against	 four	 fungal	
strains;	Candida	albicans	(AUMC	No.418),	Trichophyton	rubrum	
(AUMC	 No.	 1804),	 Aspergillus	 flavus	 (AUMC	 No.	 1276)	 and	
Fusarium	 oxysporum	 (AUMC	 No.	 5119)	 using	 Clotrimazole	 as	
control	(in	a	concentration	of	20	mg/mL).	The	results	are	listed	
in	Table	3.	It	has	been	revealed	that	mainly	five	compounds	8,	
9,	11c,	14b	 and	15c	 showed	 considerable	 antifungal	 activity	
against	 the	 tested	 fungi	 species.	 However,	 the	 4‐carbo	
hydrazide	 derivative	 (8),	 5‐[6‐(8‐hydroxyquinolin‐5‐yl)‐3‐
methyl	 pyridazin‐4‐yl]‐3‐[(4‐methoxyphenylamino)	 methyl]‐
1,3,4‐oxadiazole‐2(3H)‐thione	 derivative	 11c	 and	 its	 thio‐
triazole	 analogue	14b	 exhibited	 good	 activity	 against	Candida	
albicans,	 Aspergillus	 flavus	 and	 Fusarium	 oxysporum	 only	 in	
comparison	 with	 the	 standard	 drug	 and	 did	 not	 exhibit	
antifungal	 activity	 against	 Trichophyton	 rubrum	 and	 gave	 a	
promising	MIC,	0.08	mg/mL	against	Fusarium	oxysporum.	Also,	
the	 thiooxadiazole	 derivative	 9	 showed	 a	 moderate	 activity	
against	all	the	tested	fungi	species	except	for	Aspergillus	flavus	
(MIC,	0.08	mg/mL)	against	F.	oxysporum	(Table	3).	Finally,	the	
thio	 triazolo	 derivative	 15c	 gave	 potent	 activity	 against	
Aspergillus	 flavus	 and	 Fusarium	 oxysporum	 only	 and	 did	 not	
show	 activity	 against	 Candida	 albicans	 and	 Trichophyton	
rubrum	(MIC,	0.15	mg/mL)	against	Aspergillus	flavus.		
	
4.	Conclusion	
	
In	summary,	we	developed	an	efficient	synthesis	of	ethyl	6‐
(8‐hydroxyquinolin‐5‐yl)‐3‐methylpyridazin‐4‐carboxylate	 (4)	
via	one‐pot	three	component	reaction	of	(8‐hydroxyquinolin‐5‐
yl)(oxo)acetaldehyde	 (2),	 ethyl	 acetoacetate	 and	 hydrazine	
hydrate	in	aqueous	media.		
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Table	3.	Antifungal	activity	of	some	5‐pyridazinyl‐8‐quinolinol	derivatives	(20	mg/mL).	
*	The	amount	added	in	each	pore	is	50	μL,	AUMC	=	Assiut	University	Mycological	Center.	
	
	
Table	4.	Antifungal	activity	data	*.	
Compound	 Diameter	of	growth	of	inhibition	zone	(mm),	(MICs	(mg/L))
Candida	albicans	
AUMC.418	
Trichophyton	rubrum	
AUMC.1804	
Aspergillus	flavus	
AUMC.1276	
Fusarium	oxysporum	
AUMC.5119	
8	 10	(0.3)	 ‐	 8	(0.3) 9	(1.25)	
9	 11(1.25)	 18(5) ‐ 8(0.08)	
11c	 10	(1.25)	 ‐	 9	(0.6) 8(0.08)	
14b	 12	(2.5)	 ‐	 11	(0.6)	 9(0.08)	
15c	 ‐	 ‐	 11	(0.15)	 10	(2.5)	
Clotrimazole	 12	(0.08)	 25	(0.08)	 15	(0.15)	 14	(0.15)	
*	AUMC	=	Assiut	University	Mycological	Center.	
	
	
Moreover,	novel	heterocycles	such	as	oxadiazoles,	triazoles,	
Schiff	bases,	pyrazoles	and	fused	pyridazine	were	synthesized,	
characterized	 and	 evaluated	 as	 antimicrobial	 agents.	 The	
results	prompted	us	for	further	studies	to	exploit	the	synthetic	
potential	as	well	as	the	biological	activities	of	these	compounds	
and	other	related	in	progress.	
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Compound	 Diameter	of	growth	of	inhibition	zone	(mm)*
Candida	albicans		
AUMC.418	
Trichophyton	rubrum	
AUMC.1804	
Aspergillus flavus	
AUMC.1276	
Fusarium	oxysporum	
AUMC.5119	
4	 ‐	 ‐	 6 ‐	
8	 31	 ‐	 33 18	
9	 29	 39	 ‐ 16	
10a	 ‐	 ‐	 ‐ ‐	
11b	 ‐	 ‐	 ‐ ‐	
11c	 22	 ‐	 37 16	
12	 ‐	 ‐	 ‐ ‐	
13	 ‐	 ‐	 ‐	 ‐	
14a	 ‐	 ‐	 ‐	 ‐	
14b	 19	 ‐	 31 20	
15b	 ‐	 ‐	 ‐	 ‐	
15c	 ‐	 ‐	 33 26	
19b	 ‐	 ‐	 ‐ 8	
Clotrimazole	 24	 36	 45 22	
